DIRS.INFO The most relevant business & tech news

☆ WeightWatchers CEO just sent an internal memo to employees as stock crashes, amid debt concerns, Oprah exit
▼ + stars: | 2024-03-14 | by ( Eric Rosenbaum | ) www.cnbc.com time to read: +6 min

But since then WW shares have suffered heavy selling, dropping to a new 52-week low on Thursday. The stock, due to its debt load and short interest, as well as the general anxiety about the impact of the new weight loss drugs, is subject to heightened volatility. In the memo, Sistani told employees she wanted "to take a moment to address some of the breathless media coverage." WW shares closed at $1.87 on Thursday. It noted that WW was among companies from the weight loss industry involved in the TV event.

Persons: Oprah Winfrey, Sistani, Eli Lilly, Sima Sistani, Guggenheim, Oprah, Winfrey Organizations: CNBC, Nordisk, Guggenheim Partners, Guggenheim, WeightWatchers Clinic, FDA, WeightWatchers, National Museum of, ABC

☆ Cold water immersion benefits are not backed by quality science, report says
▼ + stars: | 2024-03-13 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +6 min

Hof attributes his success to his training method, which focuses on a commitment to practicing cold water therapy with a specific form of breathing. We have no idea if any benefits arising from the Wim Hof method could not be obtained more safely by other means,” Tifton said. “I do not agree that anyone can do things like cold water immersion.”Submerging the body in cold water is not advised for a range of medical conditions, Tipton said. “When your body hits cold water, ‘cold shock’ can cause dramatic changes in breathing, heart rate and blood pressure,” the service’s website says. Anyone who wants to try cold water therapy at home should do so carefully, and only after a thorough medical checkup.

Persons: Wim Hof, Wim, ”, Mike Tipton, Kin Cheung, —, Tipton, ” Tifton, “, “ Wim Hof, ” Tipton, Ivan Rodriguez Alba Organizations: CNN’s, CNN, Wim, University of Portsmouth, ” Hof, Guinness, Records, of Fame, Hof, National Weather Service Locations: Dutch, Hof, United Kingdom, Wim

☆ Pfizer is betting big on cancer drugs to turn business around after Covid decline – here's what to know
▼ + stars: | 2024-03-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +13 min

Now, the company is betting on cancer drugs to help it regain its footing after a rocky year marked by the rapid decline of its Covid business. That $43 billion Seagen acquisition doubled Pfizer's oncology drug pipeline to 60 different experimental programs. Some analysts noted that it might take a few years for some of Pfizer's cancer drugs in mid-stage development to show pivotal clinical trial data and become less risky. Revenue from the blockbuster breast cancer drug Ibrance and prostate cancer treatment Xtandi, which Pfizer shares with Astellas Pharma, has declined over the past year. They are among the most expensive prescription drugs in the U.S. Before the Seagen deal, 94% of Pfizer's cancer products were small-molecule drugs.

Persons: Wall, Seagen, Chris Boshoff, Boshoff, David Ryder, Trung Huynh, Joe Biden's, Chris Schott, Suneet Varma, RemeGe, Merck, Padcev, Guggenheim, Pfizer's, Pfizer hasn't, Dr, Mikael Dolsten, Irfan Khan Organizations: Nurphoto, Getty, Pfizer, Astellas Pharma, Guggenheim, Bloomberg, UBS, Medicare, Drug Administration, FDA, ADC, JPMorgan, Drugs, CNBC, CVS Pharmacy, Los Angeles Times Locations: Covid, Bothell , Washington, U.S, biologics, China, Eagle Rock , California

☆ Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move
▼ + stars: | 2024-03-08 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly said Friday that the Food and Drug Administration has pushed back its approval decision deadline for the drugmaker's experimental Alzheimer's treatment donanemab in a surprise move. The agency plans to call a last-minute meeting of its outside advisors to further review the treatment's safety and efficacy in a late-stage trial, Eli Lilly said. It's another setback for Eli Lilly, which is racing to compete with Biogen and Eisai. In 2021, the FDA approved an earlier, ill-fated Alzheimer's drug called Aduhelm from Biogen and Eisai, despite a negative recommendation from the agency's advisory panel.

Persons: Eli Lilly, Eli Lilly's, Leqembi, Anne White Organizations: and Drug Administration, FDA Locations: Indianapolis , Indiana, Biogen

☆ Ken Griffin Gifts $50 Million to University of Miami Cancer Center
▼ + stars: | 2024-03-05 | by ( Tiara White | ) www.businessinsider.com time to read: +3 min

Ken Griffin gave $50 million to the Sylvester Comprehensive Cancer Center, part of the University of Miami's medical school, to help advance cancer research, according to a press release. AdvertisementA rendering of the Kenneth C. Griffin Cancer Research Building. Since moving to Miami, Griffin has been making his mark on the Sunshine State, including a slew of charitable gifts and big real-estate purchases. The new building, to be named the Kenneth C. Griffin Cancer Research Building, is set to be one of the largest stand-alone buildings for cancer research in Florida, the University of Miami's press release said. AdvertisementThe Sylvester Comprehensive Cancer Center in Miami University of Miami"The Ken Griffin name has become synonymous with philanthropic leadership that drives value in the communities in which he operates," Stuart A. Miller, the board chair of the University of Miami Health System, said.

Persons: —, Ken Griffin, Griffin, I'm, Kenneth C, He's, It's, Stuart, Miller Organizations: Service, Citadel, Cancer Center, University of, Business, Harvard, Faculty of Arts and Sciences, Harvard Crimson, Griffin Cancer Research, University of Miami, Miami —, Sunshine, Citadel Securities, Forbes, University of Miami's, Miami University of Miami, University of Miami Health Locations: Florida, Chicago, Miami, New York

☆ Morgan Stanley thinks this little-known autoimmune biotech stock can surge more than 40%
▼ + stars: | 2024-03-04 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Newly public biotech Kyverna Therapeutics could be a blockbuster cell therapy developer for autoimmune disease, according to Morgan Stanley. The stock opened at $34.25, above the initial public offering price of $22 per share, and closed Friday at $27.75. Although the data from KYV-101 is limited, Ulz wrote that he's "highly encouraged given promising results across multiple indications, multiple sites, and in challenging patients." The analyst pointed out that cell therapies have "meaningfully improved" the treatment of B-cell cancers and that multiple therapies are currently approved, increasing the therapies' potential to treat autoimmune diseases. Ingenui-T is a next-generation process in preclinical development for manufacturing autologous anti-CD19 CAR T-cell therapy, and uses the same CAR construct as KYV-101, Kyverna said.

Persons: Morgan Stanley, Michael Ulz, Kyverna, Ulz Organizations: Therapeutics, Nasdaq, autoimmunity Locations: KYV, Kyverna

☆ Viking Therapeutics emerges as a strong weight loss drug player — or takeover target
▼ + stars: | 2024-03-03 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +8 min

In this article VKTX Follow your favorite stocks CREATE FREE ACCOUNTCr | Istock | Getty ImagesBiotech company Viking Therapeutics has emerged as a strong potential entrant — or takeover target — in the budding weight loss drug market. Their treatments sparked the weight loss drug industry gold rush over the past year despite their hefty price tags and barriers to insurance coverage. It's too early to say whether Viking's drug could have an edge over existing or developing weight loss treatments. The pharmaceutical giant could also launch a slate of other weight loss treatments over the next few years that may have advantages over Zepbound, whether they offer more weight loss or convenience. That could give Viking the commercial and manufacturing capabilities needed to compete in the weight loss drug market.

Persons: Eli Lilly, Eli Lilly's Zepbound, Viking, Goldman Sachs, Eli Lilly’s, Brendan Mcdermid, GLP, Brian Lian, William Blair, Andy Hsieh, Hsieh, Eli Lilly's, Jefferies, Akash Tewari, doesn't, Mike Segar, Lian, William Blair's Hsieh, Oppenheimer, Jay Olson Organizations: Getty Images Biotech, Viking Therapeutics, Novo Nordisk, Reuters, Viking, Novo, U.S . Food, Drug Administration, Company, Deutsche Bank, CNBC Locations: New York City, Branchburg , New Jersey

☆ Opinion | Three Mothers’ Plea to the F.D.A.: Save Our Children
▼ + stars: | 2024-02-28 | by ( ) www.nytimes.com time to read: +1 min

To the Editor:Re “Why Can’t More Children Get the Treatment That Saved My Son’s Life?,” by Elizabeth Currid-Halkett (Opinion guest essay, Feb. 24):Our three children, ages 5 and 7, battle a rare, relentless and ultimately fatal disease called cystinosis. We recently found hope in the initial phase of a gene therapy clinical trial that was shown to be safe and yielded very promising results — a therapy that could one day save our children’s lives. Our biggest fear is that it will not be accessible to them or others in desperate need. We applaud Dr. Marks’s wisdom and perspective. reviewers’ initial rejection is a cautionary tale of how patient access to lifesaving therapies could be impeded by a narrow interpretation of efficacy.

Persons: Elizabeth Currid, Currid, Peter Marks, “ Organizations: Biologics

☆ Wall Street thinks this revolutionary gut health stock can triple in value
▼ + stars: | 2024-02-27 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +4 min

Just weeks after its initial public offering, Fractyl Health is catching Wall Street's attention as the next potential biopharmaceutical darling. Analysts are highlighting the company's groundbreaking therapies that directly target the gut and pancreas to ultimately induce Type 2 diabetes maintenance and weight loss. "Growing evidence indicates the gut is a core regulator of metabolism, placing gut dysfunction as a root cause of metabolic disease. Indeed, emerging consensus links modern diets to changes in the gut and pancreas that in turn increase an individual's risk of developing Type 2 Diabetes and obesity," Ulz wrote. gut) root cause of disease, could result in a more durable, disease-modifying treatment, differentiated from current, more burdensome (i.e.

Persons: Morgan Stanley, Jason Gerberry, Michael Ulz's, Ulz, Gerberry, Rejuva, America's Gerberry Organizations: Bank of America, Evercore ISI, Fractyl's, Bank, America's Locations: Fractyl

☆ Viking stock doubled Tuesday. Here's where the next moves in the obesity space could come from
▼ + stars: | 2024-02-27 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

VKTX YTD mountain Viking shares year to date Then, Viking shares more than doubled in trading on Tuesday, putting the stock on pace to report a more than 300% year-to-date gain, after the company said its GLP-1/GIP receptor agonist VK2735 hit all its primary goals in a phase 2 clinical trial. The Tema Cardiovascular and Metabolic ETF (HRTS) , which is up 12% year to date, owns Novo, Lilly and Viking. Still early days Some analysts and investors admit it is still very early days for obesity treatment and many questions remain to be answered. "We continue to expect above consensus growth in the space, as we are bullish on adoption from payers and broader obesity uptake," Meacham wrote. For obesity only, Lilly has already gained a 38% share, despite only being in the market for 13 weeks, he said.

Persons: Eli Lilly, Geoff Meacham, Meacham, Lilly, Yuri Khodjamirian, Khodjamirian, Jeff Jonas, Becton Dickinson, Novo, BofA's Meacham, What's, Tema's, it's, Gabelli's Jonas, he's, William Blair, Andy Hsieh, Hsieh Organizations: Novo Nordisk, Bank of America, Centers for Disease Control, Zealand Pharma, Viking Therapeutics, Zealand, Food and Drug Administration, Novo, Metabolic, Therapeutics, Pharmaceuticals, Rock, AstraZeneca, Roche, Gabelli Funds, FDA, Viking, Merck, Pfizer Locations: U.S, Tema, Novo Nordisk's, GLP, Lilly

☆ Opinion | Shining a Light on Long Covid, a ‘Vicious Affliction’
▼ + stars: | 2024-02-27 | by ( ) www.nytimes.com time to read: +1 min

To the Editor:Re “Could Long Covid Be the Senate’s Bipartisan Cause?,” by Zeynep Tufekci (column, Feb. 20):Like one of the people you interviewed, I, too, was an “Energizer bunny” before I contracted Covid. However, two active Covid infections within three months — in June and August of 2022 — left me virtually bedridden with long Covid for 18 months. To add insult to injury, there are too many dismissive doctors who treat long Covid in an ineffective manner and believe that long Covid is largely a psychological issue. We need strong, consistent funding and relentless, targeted research to identify effective diagnostic testing and successful therapies. We need to require insurance companies to fund experimental or off-label usage of pharmaceuticals and nutraceuticals (food products with health benefits).

Persons: Long, Zeynep Tufekci, Covid, —

☆ Cost of sickle cell therapies correction
▼ + stars: | 2024-02-26 | by ( ) www.cnbc.com time to read: 1 min

Eli Lilly is not suing the Biden administration over the Inflation Reduction Act. An earlier version of this story misstated that.

Persons: Eli Lilly Organizations: Biden

☆ Meet the DIPS parents: Double Income, Public School. They've got it better than the POLKs, or Parents of Little Kids.
▼ + stars: | 2024-02-25 | by ( Katie Notopoulos | ) www.businessinsider.com time to read: +6 min

But the double whammy of housing plus childcare costs doesn't hit all parents — just parents of very young kids. However, after-school programs or an afternoon babysitter are typically a fraction of the cost of full-time day care.) I propose we call them: DIPS, or Double Income, Public School. For example, Massachusetts has the highest average childcare costs, where day care for an infant is $24,472. I'm stuck in between — one kid in public school and a younger one still in day care.

Persons: —, Alcynna Lloyd, Lloyd, Zillow, it's, I'm, Rich, Stanley, you'll, they'll, POLK Organizations: Service, Business, Public School, Kids, Nationwide Locations: Los Angeles, San Diego, California, Massachusetts, Iowa, In Massachusetts

☆ 5 tips for navigating childhood obesity
▼ + stars: | 2024-02-24 | by ( Andrea Kane | ) edition.cnn.com time to read: +6 min

Editor’s note: Season 9 of the podcast “Chasing Life With Dr. Sanjay Gupta” explores the intersection between body weight and health. With children, doctors define obesity a bit differently than they do with adults. Severe obesity is having a BMI equal to or greater than the 120th percentile. “Most people who are heavy by the age of 5 or 6 will tend to continue to have problems with body weight throughout adolescence and into adulthood,” Yanovski said. “We know that those individuals will therefore accrue the greatest risks from their higher body (fat) because they’re going to continue to have high body weight throughout the years,” he said.

Persons: Sanjay Gupta ”, Dr, Jack Yanovski, Sanjay Gupta, ” Yanovski, ”, pediatricians, “ Organizations: CNN, National Institute of Child Health, Human Locations: Alabama

☆ New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle
▼ + stars: | 2024-02-23 | by ( Bertha Coombs | ) www.cnbc.com time to read: +2 min

The approval of two gene therapies to treat sickle cell disease has given hope to patients who suffer from the debilitating disease, which overwhelmingly affects Black people and people of color. Sickle cell has forced him to leave his job and at times taken him away from his family. Still, he's hesitant to try the new one-time gene therapies because they require months of intensive medical preparation, including chemotherapy, to prepare patients' bone marrow stem cells for extraction and gene editing. Vertex Pharmaceuticals ' gene therapy Casgevy lists for $2.2 million, while Bluebird Bio 's treatment Lyfgenia lists for $3.1 million. Kanter said it will take time to ramp up capacity and to set up facilities across the country to treat patients at scale.

Persons: Michael Goodwin, Goodwin, I've, I'm, he's, …, Goodwin's hesitancy, Julie Kanter, Kanter Organizations: Health, Vertex Pharmaceuticals, University of Alabama, National Alliance of Sickle Cell Centers, for Disease Control, National Alliance of Sickle Cell Locations: Birmingham

☆ New sickle cell gene therapies are a breakthrough, but prices are still too high
▼ + stars: | 2024-02-23 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNew sickle cell gene therapies are a breakthrough, but prices are still too highCNBC's Bertha Coombs joins 'Power Lunch' to report on the expensive cost of gene therapy.

Persons: Bertha Coombs

☆ A 21-year-old had a stroke at graduation as a rare side effect of birth control. She wants people of all ages to know the signs and risk factors.
▼ + stars: | 2024-02-23 | by ( Serafina Kenny | ) www.businessinsider.com time to read: +6 min

Marissa Fattore, 21, had a stroke at her graduation ceremony. On her college graduation day, Marissa Fattore woke up feeling "off." CVST occurs when blood clots block the venous sinuses in the brain, stopping blood from draining out. No more than 10 in 10,000 people a year develop blood clots as a result of being on birth control, according to Cleveland Clinic, compared to the 1 to 5 per 10,000 people who develop blood clots each year and aren't on hormonal birth control. She wants people to know that cardiovascular disease can happen to anyone and that learning the warning signs could help save a life.

Persons: Marissa Fattore, Fattore, she'd, Pratima Gupta Organizations: Kutztown University of Pennsylvania, American Heart Association, Women Class, of Obstetrics, Gynecology, Reproductive Sciences, UC San Diego Health, Cleveland Clinic

☆ Here are Tuesday's biggest analyst calls: Nvidia, Apple, Tesla, JetBlue, Disney, Caterpillar, Super Micro and more
▼ + stars: | 2024-02-20 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

Here are Tuesday's biggest calls on Wall Street: Morgan Stanley downgrades Oatly to equal weight from overweight Morgan Stanley resumed coverage of the oats company and said it sees too many negative catalysts. " Morgan Stanley reiterates Tesla as overweight Morgan Stanley said it's sticking with Tesla despite a slew of negative data points in a recent investor survey. Morgan Stanley reiterates Nvidia as overweight Morgan Stanley said it's standing by Nvidia heading into earnings later this week. Morgan Stanley initiates CG Oncology as buy Morgan Stanley said shares of the bladder cancer company are "compelling." "We initiate coverage on Morgan Stanley Direct Lending with a Buy rating and $23.50 PT.

Persons: Morgan Stanley downgrades Oatly, Morgan Stanley, Tesla, Bernstein, Siri, it's, Disney, Ingersoll Rand, Rosenblatt, MSCI's, Goldman Sachs, Wolfe, Piper Sandler, Riley, Grainger, Northcoast, JPMorgan downgrades Holley Organizations: Apple, Nvidia, Disney, RBC, Aerospace, BAE Systems, Caterpillar, SMCI, Deutsche Bank, JetBlue, Alaska Air, ASM, Health, BrightSpring Health, Brunswick Corporation, Barclays, JPMorgan, Mizuho, Oncology, UBS, Morgan, Fund, Seaport, Booking Holdings, " Bank of America, AIG, Bank of America, General Insurance Locations: Silicon Valley, Alaska, Brunswick, MIBS, Texas, Europe, Asia

☆ Gene Therapies Could Transform Rare Diseases. Are We Holding Them Back? - The New York Times
▼ + stars: | 2024-02-19 | by ( Elizabeth Currid-Halkett | ) www.nytimes.com time to read: +1 min

On Jan. 8, 2020, as I was parking my car, I got a long-awaited phone call from one of my son’s doctors. She informed me that our 7-month-old son, Eliot, had Duchenne muscular dystrophy, a fatal neuromuscular disease. I can see my neighbor walking up her steps with groceries, a leaf falling, oblivious to the devastation below. It is caused by a genetic mutation on the X chromosome, thus the disease almost exclusively affects boys (one in 3,300). lose muscle mass and thus the ability to do basic things like run and walk.

Persons: Eliot, Joan Didion, D.M.D, Jerry Mendell Organizations: Nationwide Children’s Hospital, D.M.D Locations: Columbus , Ohio

☆ 'This is the mental health moment': Innovation and M&A are helping to boost these stocks to new heights
▼ + stars: | 2024-02-19 | by ( Michelle Fox | ) www.cnbc.com time to read: +14 min

There's been a lot of chatter about the mental health crisis since the Covid-19 pandemic. Attention to a long-time crisis The mental health crisis is nothing new. However, there has also been a growing awareness and acceptance of mental health illnesses over the past decade, said Canaccord Genuity analyst Richard Close. "There's been recognition that mental health has a significant impact on a person's overall health," he said. "This is the mental health moment," said Dr. Ken Duckworth, NAMI's chief medical officer and author of "You Are Not Alone: The NAMI Guide to Mental Health."

Persons: There's, Covid, Peter Micca, AbbVie, Emraclidine, Myers Squibb, Karuna, Marc Goodman, Canaccord, Richard Close, MacKenzie Scott, Ken Duckworth, NAMI, Deloitte's Micca, William Blair, Myles Minter, Minter, Auvelity, Leerink's Goodman, Ashwani Verma, Verma, Goodman, BioHaven, Cerevel, Neumora, tardive, David Song, BetterHelp, psychedelics Johnson, Johnson, Spravato, Blair's Minter, Axsome, Micca, Michael Bloom Organizations: Institute for Health Metrics, Deloitte, Cerevel Therapeutics, Karuna Therapeutics, Bristol Myers, Leerink Partners, Centers for Disease Control, National Alliance, Mental, Mental Health, Wall Street, Therapeutics, Neumora Therapeutics, UBS, Karuna, Cellular Therapies, Xenon Pharmaceuticals, Neurocrine Biosciences, Acadia Pharmaceuticals, Tema Neuroscience, Axsome Therapeutics, Acadia Healthcare, BetterHelp, CNBC, pharma, Cellular Locations: Covid, Bristol, XEN1101, Acadia, Tema

☆ Psilocybin: These athletes suffered life-changing injuries. Then, they turned to psychedelics.
▼ + stars: | 2024-02-19 | by ( Amy Woodyatt | ) edition.cnn.com time to read: +17 min

Last year, Australia became the first country in the world to legalize clinical prescribing of MDMA, more commonly known as ecstasy, and psilocybin for certain mental health disorders. Elite athletes experience mental health disorder symptoms and psychological distress at similar, if not higher, rates to the general population, researchers pointed out in a study published in the Journal of Applied Sport Psychology. Researchers in the field say that psychedelics are shown to work when treating some mental health conditions. Later, he founded Wesana Health, a biotechnology company which focuses on developing psychedelic medicine for mental health, the most recent being a CBD and psilocybin-based drug. Since her retirement as a professional athlete, Symonds explains that she uses psychedelic drugs for clarity, though not under the direction of a doctor.

Persons: CNN — Daniel Carcillo, Carcillo, ”, Jeff Gross, “, –, Aaron Rodgers, ayahuasca, Dustin Satloff, ” Rodgers, Mike Tyson, Dana White, Courtney Walton, ” Walton, Jeff Novitzky, White, Novitzky, Johns Hopkins, we’ve, ‘, ’ ”, Chris Unger, ” Robin Carhart, Harris, Ralph Metzner, University of California San Francisco, psychedelics, ” Carhart, Carhart, psychedelics aren’t, ” James Rucker, ” Rucker, I’ve, Jonathan Daniel, Lucy, Anna Symonds, Symonds, James MacDonald, Rucker, “ They’re Organizations: CNN, Canadian, NHL, Philadelphia Flyers, New York Rangers, Los Angeles Kings, Chicago Blackhawks, CNN Sport, ” Sporting, Harvard Health, Oregon, UFC, Elite, Applied Sport Psychology, Melbourne School of Psychological Sciences, Athlete Health, University of Miami, Neurology, Psychiatry, University of California San, Centre for Psychedelic Research, Imperial College London, King’s College London, Imperial College of London, Getty, Wesana Health, US Food and Drug Administration, NASDAQ, Lucy Scientific, Former US, Addiction Center, US National Institutes of Health, Numinus Bioscience, Bloomberg, Prevention, Befrienders Locations: Denver, Colorado, psychedelics, Australia, “, Nanaimo

☆ What Zyn pouches do to your brain, body, and heart
▼ + stars: | 2024-02-16 | by ( Kim Schewitz | ) www.businessinsider.com time to read: +5 min

Zyn nicotine pouches are popping up everywhere. Someone using a 3 mg Zyn pouch will absorb 1.59 mg of nicotine, or 3.51 mg from a 6 mg pouch, a spokesperson for Zyn told Business Insider in an email. Middle and high-school-aged kids are using nicotine pouchesZyn says its products are only for consumers 21 and older who already use nicotine. However, unlike nicotine replacement therapies such as gum, patches, and mints, nicotine pouches like Zyn have not yet been proven to be a safe way to quit smoking. A 2023 study published by the Centers for Disease Control and Prevention found that around 1.5% of middle and high school students reported using nicotine pouches in the last 30 days.

Persons: Tucker Carlson, Bellini, Dr, Jonathan Foulds, Brittney Keller, Hamilto, Panagis, Alok Patel Organizations: Business, Penn State University College of Medicine, New York Times, Zyn, National Institute on Drug, Centers for Disease Control, CDC, The Ohio State University College of Medicine, Johns Hopkins Medicine, Stanford Children’s Hospital, ABC

☆ Morgan Stanley ponders if Eli Lilly could be the first $1 trillion pharma stock on weight loss boom
▼ + stars: | 2024-02-16 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +3 min

On Friday, Flynn raised his price target on Lilly shares to $950 from $805. With Lilly's stock closing Thursday at $757.78, the target suggests 25% more upside ahead. LLY 1Y mountain Eli Lilly shares over the past year. "LLY is establishing high barriers to entry in the diabesity market," Flynn said, adding that this is what contributes to its higher valuation. Phase 3 data is expected on orforglipron in 2025, which Flynn sees as a catalyst for the stock to go higher.

Persons: Eli Lilly, Morgan Stanley, Terence Flynn, Flynn, Lilly, Mounjaro, — CNBC's Michael Bloom Organizations: Novo Nordisk Locations: diabesity

☆ What Eli Lilly investors can learn from the slow launch of a competitor's drug
▼ + stars: | 2024-02-15 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +8 min

Club holding Eli Lilly is expecting to get approval for its Alzheimer's treatment in the coming weeks, but investors looking for immediate financial success should temper their expectations. The FDA's decision on Lilly's drug, known as donanemab, is expected by the end of March. In the meantime, Eli Lilly's diabetes and obesity drugs, the heart of our investment thesis, should continue to fuel the lion's share of the company's topline growth. About 2,000 patients are currently taking Leqembi, Biogen said Tuesday, up from 800 at the time of the company's third-quarter report in November. LLY YTD mountain Eli Lilly's stock performance so far in 2024.

Persons: Eli Lilly, drugmaker Biogen, Eli Lilly's, —, Lilly, Biogen, Japan's, Chris Viehbacher, Viehbacher, Morgan Stanley, Lilly's, Donanemab, Mounjaro, Jim Cramer, Leqembi, Jim Cramer's, Jim Organizations: Food and Drug Administration, Drug Administration, Alzheimer's Association, FDA, Club, GE Healthcare, FactSet, Pharmaceutical, CNBC Locations: Indianapolis

☆ Biden administration examining role of supply chain middlemen in generic drug shortages
▼ + stars: | 2024-02-14 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

They are group purchasing organizations, which broker drug purchases for hospitals and other health-care providers, and drug wholesalers, which buy medicines from manufacturers and distribute them to providers. But the Biden administration is zeroing in on other players in the drug supply chain to uncover the "root causes and potential solutions" to ongoing shortages. The Federal Trade Commission on Wednesday said it is examining the role that drug wholesalers and companies that purchase medicines for U.S. health-care providers play in shortages of generic drugs, which account for the majority of Americans' prescriptions. Group purchasing organizations and wholesalers have gotten limited attention on Capitol Hill, even as reining in high drug costs has become a key priority among lawmakers in both chambers. PBMs contend that manufacturers are responsible for high drug prices, while drugmakers say rebates and fees collected by those middlemen force them to increase list prices for products.

Persons: Biden, Doug Farrar, Cencora Organizations: FTC, Department of Health, Human Services, Federal Trade Commission, Public Affairs, CNBC, HHS, Cardinal Health, Group, Capitol, CNBC PRO Locations: U.S

Search resuls for: "Therapies"

25 mentions found